Breakthrough EU approval for Dupixent offers new hope for children with eosinophilic esophagitis

Breakthrough EU approval for Dupixent offers new hope for children with eosinophilic esophagitis

The European Medicines Agency (EMA) has granted approval for Dupixent, a therapy developed by Sanofi and Regeneron, to treat eosinophilic esophagitis (EoE) in children as young as one year old. This decision marks a critical step in addressing a condition that has left young patients and their families with limited options. With this approval, Dupixent […]

EMA approves Dupixent as first biologic for COPD with elevated eosinophils

EMA approves Dupixent as first biologic for COPD with elevated eosinophils

The European Medicines Agency (EMA) has granted approval to Dupixent (dupilumab) as a novel add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterized by elevated blood eosinophils. This marks the first time Dupixent, jointly developed by Sanofi and Sanofi and Regeneron, is approved for this specific patient group within the European […]

Sanofi, Regeneron get Dupixent EC approval for eosinophilic esophagitis

Sanofi, Regeneron get Dupixent EC approval for eosinophilic esophagitis

French pharmaceutical company Sanofi and Regeneron, an American biotechnology company, have received the approval of the European Commission (EC) to market their Dupixent (dupilumab) injection in the European Union for eosinophilic esophagitis (EoE). Dupixent is indicated in adults and adolescents 12 years and over, who are not candidates for conventional medicinal treatment. With the approval, […]

Dupixent receives FDA approval for treatment of moderate-to-severe asthma

Dupixent receives FDA approval for treatment of moderate-to-severe asthma

Sanofi and Regeneron Pharmaceuticals’ Dupixent (dupilumab) has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) approving it as an add-on maintenance therapy for two specific types of asthma. This latest approval marks a pivotal advancement for patients with moderate-to-severe asthma. New FDA Approval for Dupixent: Key Details The FDA’s green light […]

Sanofi and Regeneron’s Dupixent receives FDA approval for atopic dermatitis treatment

Dupixent (dupilumab), the co-developed eczema injection from pharma giants Sanofi and Regeneron Pharmaceuticals, has got the US FDA approval for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients.

Sanofi and Regeneron’s Dupixent receives FDA approval for atopic dermatitis treatment

Sanofi and Regeneron Pharmaceuticals have announced a significant advancement in dermatological care with the U.S. Food and Drug Administration (FDA) approving Dupixent (dupilumab) for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients. This marks Dupixent as the first biologic medication approved for patients who have not responded adequately to traditional topical prescription treatments […]

Sanofi and Regeneron’s Dupixent shows promising results in Phase 3 eczema trial

The jointly developed eczema drug, Dupixent (dupilumab) from Sanofi and Regeneron Pharmaceuticals has succeeded in a pivotal phase 3 Atopic dermatitis clinical trial.

Sanofi and Regeneron’s Dupixent shows promising results in Phase 3 eczema trial

Sanofi and Regeneron Pharmaceuticals have achieved a significant milestone with their jointly developed eczema drug, Dupixent (dupilumab), meeting the primary endpoints in a year-long Phase 3 clinical trial for adults with uncontrolled moderate-to-severe atopic dermatitis (AD). Breakthrough in Atopic Dermatitis Treatment The CHRONOS trial, a critical phase 3 study, involved Dupixent administered alongside topical corticosteroids […]